MCID: LNG031
MIFTS: 51

Lung Benign Neoplasm

Categories: Cancer diseases, Respiratory diseases

Aliases & Classifications for Lung Benign Neoplasm

MalaCards integrated aliases for Lung Benign Neoplasm:

Name: Lung Benign Neoplasm 12 15
Lung Neoplasms 43 71
Tumor of the Lung 12
Lung Tumor 54

Classifications:



External Ids:

Disease Ontology 12 DOID:3683
MeSH 43 D008175
NCIt 49 C3200
SNOMED-CT 67 126713003
UMLS 71 C0024121

Summaries for Lung Benign Neoplasm

MalaCards based summary : Lung Benign Neoplasm, also known as lung neoplasms, is related to lung adenoma and bronchus cancer, and has symptoms including hemoptysis An important gene associated with Lung Benign Neoplasm is NKX2-1 (NK2 Homeobox 1), and among its related pathways/superpathways are Gastric cancer and Pathways in cancer. The drugs Terbutaline and Ipratropium have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and testes, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Lung Benign Neoplasm

Diseases related to Lung Benign Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 903)
# Related Disease Score Top Affiliating Genes
1 lung adenoma 31.8 TP53 SFTPC SCGB1A1 RARB KRAS HRAS
2 bronchus cancer 31.4 GRP FHIT ENO2 EGFR
3 granular cell tumor 30.9 SYP NKX2-1 ENO2
4 glomus tumor 30.7 TP53 SYP ENO2 CDKN2A
5 angiosarcoma 30.6 TP53 KRT7 KRAS
6 perivascular epithelioid cell tumor 30.6 SYP NKX2-1 CDKN2A
7 thyroid carcinoma 30.6 NKX2-1 HRAS FHIT
8 exanthem 30.5 KRAS HRAS EGFR
9 alveoli adenoma 30.4 SFTPC SCGB1A1 NKX2-1
10 in situ carcinoma 30.4 TP53 HRAS EGFR CDKN2A
11 epithelial-myoepithelial carcinoma 30.4 TP53 KRT7 HRAS
12 myoepithelial carcinoma 30.4 TP53 KRT7 HRAS
13 carcinoid tumors, intestinal 30.4 SYP NKX2-1 ENO2 CHGA
14 pulmonary sclerosing hemangioma 30.4 SYP NKX2-1 KRT7 ENO2 CHGA
15 squamous cell papilloma 30.3 TP53 HRAS CDKN2A
16 malignant peripheral nerve sheath tumor 30.3 TP53 KRT7 EGFR CDKN2A
17 mucoepidermoid carcinoma 30.3 TP53 NKX2-1 KRT7 EGFR CHGA CDKN2A
18 sclerosing hemangioma 30.3 SYP NKX2-1 KRT7 ENO2 CHGA
19 pleural cancer 30.3 TP53 EGFR CDKN2A
20 myoblastoma 30.3 SYP ENO2
21 epithelioid sarcoma 30.3 SYP KRT7 EGFR
22 pleomorphic rhabdomyosarcoma 30.2 TP53 SYP KRT7
23 vascular cancer 30.2 TP53 SYP KRT7
24 oncocytoma 30.2 SYP NKX2-1 KRT7 KRT20
25 hemangioma 30.2 TP53 SYP NKX2-1 KRT7 KRAS ENO2
26 malignant pleural mesothelioma 30.2 TP53 NKX2-1 EGFR CDKN2A
27 pleural disease 30.2 TP53 EGFR CDKN2A
28 sertoli-leydig cell tumor 30.2 SYP KRT7 ENO2
29 hemangioblastoma 30.2 SYP ENO2 EGFR
30 large cell neuroendocrine carcinoma 30.2 SYP NKX2-1 NCAM1 KRT7 KRT20 ENO2
31 esophagus adenocarcinoma 30.1 TP53 EGFR CDKN2A
32 neuroendocrine carcinoma 30.1 SYP NKX2-1 NCAM1 KRT7 KRT20 GRP
33 lymphangioma 30.1 TP53 KRAS HRAS EGFR
34 glomangiosarcoma 30.1 SYP NCAM1
35 thyroid tumor 30.1 TP53 KRAS HRAS
36 carcinoid syndrome 30.1 SYP ENO2 CHGA
37 esophagitis 30.1 TP53 FHIT EGFR CDKN2A
38 lymphoepithelioma-like carcinoma 30.1 KRT7 KRT20 ENO2
39 familial adenomatous polyposis 30.1 TP53 MGMT KRAS HRAS
40 lung oat cell carcinoma 30.1 SYP GRP ENO2 CHGA
41 pleomorphic adenoma 30.1 TP53 KRT7 HRAS CDKN2A
42 sweat gland cancer 30.1 TP53 SYP KRT7 KRT20
43 appendix adenocarcinoma 30.1 SYP KRT7 KRT20 KRAS HRAS CHGA
44 pulmonary adenocarcinoma in situ 30.1 SFTPC NKX2-1 KRAS HRAS EGFR
45 papillary adenocarcinoma 30.1 TP53 NKX2-1 KRT7 KRAS HRAS
46 mucinous adenocarcinoma 30.1 TP53 NKX2-1 KRT7 KRT20 KRAS EGFR
47 carcinosarcoma 30.0 TP53 KRT7 KRAS HRAS EGFR CDKN2A
48 lung disease 30.0 TP53 SFTPC SCGB1A1 NKX2-1 GRP ENO2
49 bronchiolo-alveolar adenocarcinoma 30.0 NKX2-1 KRT7 KRT20 KRAS FHIT EGFR
50 adenocarcinoma in situ 30.0 KRT7 KRT20 KRAS HRAS EGFR CDKN2A

Graphical network of the top 20 diseases related to Lung Benign Neoplasm:



Diseases related to Lung Benign Neoplasm

Symptoms & Phenotypes for Lung Benign Neoplasm

UMLS symptoms related to Lung Benign Neoplasm:


hemoptysis

GenomeRNAi Phenotypes related to Lung Benign Neoplasm according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.91 EGFR HRAS KRAS NCAM1
2 Decreased viability GR00055-A-2 9.91 EGFR HRAS KRAS
3 Decreased viability GR00055-A-3 9.91 KRAS
4 Decreased viability GR00106-A-0 9.91 KRAS
5 Decreased viability GR00221-A-1 9.91 EGFR HRAS KRAS
6 Decreased viability GR00221-A-2 9.91 HRAS KRAS
7 Decreased viability GR00221-A-3 9.91 HRAS
8 Decreased viability GR00221-A-4 9.91 EGFR
9 Decreased viability GR00301-A 9.91 KRAS
10 Decreased viability GR00381-A-1 9.91 KRAS
11 Reduced mammosphere formation GR00396-S 9.17 CHGA EGFR HRAS KRAS KRT7 NCAM1

MGI Mouse Phenotypes related to Lung Benign Neoplasm:

45 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.33 CDKN2A ENO2 GRP HRAS KRAS NCAM1
2 cardiovascular system MP:0005385 10.31 CDKN2A CHGA EGFR GRP HRAS KRAS
3 cellular MP:0005384 10.3 CDKN2A EGFR ENO2 KRAS KRT7 NCAM1
4 mortality/aging MP:0010768 10.28 CDKN2A CHGA EGFR FHIT HRAS KRAS
5 endocrine/exocrine gland MP:0005379 10.26 CDKN2A CHGA EGFR HRAS KRAS MGMT
6 homeostasis/metabolism MP:0005376 10.25 CDKN2A CHGA EGFR FHIT HRAS KRAS
7 growth/size/body region MP:0005378 10.23 CDKN2A CHGA EGFR ENO2 HRAS KRAS
8 digestive/alimentary MP:0005381 10.19 CDKN2A EGFR FHIT HRAS KRAS NKX2-1
9 nervous system MP:0003631 10.17 CDKN2A CHGA EGFR ENO2 GRP HRAS
10 neoplasm MP:0002006 10.15 CDKN2A EGFR FHIT HRAS KRAS MGMT
11 craniofacial MP:0005382 10.05 EGFR ENO2 HRAS KRAS RARB STK11
12 no phenotypic analysis MP:0003012 9.96 CDKN2A CHGA EGFR HRAS KRAS MGMT
13 normal MP:0002873 9.85 EGFR HRAS KRAS NKX2-1 RARB RASSF1
14 renal/urinary system MP:0005367 9.61 CHGA EGFR HRAS KRAS KRT7 RARB
15 respiratory system MP:0005388 9.44 CDKN2A EGFR ENO2 GRP HRAS KRAS

Drugs & Therapeutics for Lung Benign Neoplasm

Drugs for Lung Benign Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 691)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Terbutaline Approved Phase 4 23031-25-6 5403
2
Ipratropium Approved, Experimental Phase 4 60205-81-4, 22254-24-6 43232 657309
3
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
4
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
5
Dalteparin Approved Phase 4 9005-49-6
6
Tinzaparin Approved Phase 4 9041-08-1, 9005-49-6 25244225
7
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
8
Alfentanil Approved, Illicit Phase 4 71195-58-9 51263
9
Remifentanil Approved Phase 4 132875-61-7 60815
10
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
11
Tropisetron Approved, Investigational Phase 4 89565-68-4, 105826-92-4 5595
12
Dabrafenib Approved, Investigational Phase 4 1195765-45-7 44462760 44516822
13
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
14
Desflurane Approved Phase 4 57041-67-5 42113
15
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
16
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
17
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
18
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
19
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
20
Acetaminophen Approved Phase 4 103-90-2 1983
21
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
22
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
23
Vemurafenib Approved Phase 4 918504-65-1 23252090 42611257
24
Methotrexate Approved Phase 4 59-05-2, 1959-05-2 126941
25
Imidacloprid Vet_approved Phase 4 105827-78-9 86418
26 Opiate Alkaloids Phase 4
27 Heparin, Low-Molecular-Weight Phase 4
28 calcium heparin Phase 4
29 Excitatory Amino Acid Antagonists Phase 4
30 Anesthetics, Dissociative Phase 4
31 Diphosphonates Phase 4
32
Bilirubin Phase 4 69853-43-6, 635-65-4 21252250 5280352
33 Antidotes Phase 4
34 N-monoacetylcystine Phase 4
35 Anesthetics, Inhalation Phase 4
36 Serotonin Uptake Inhibitors Phase 4
37 Antipsychotic Agents Phase 4
38 Narcotics Phase 4
39 Anesthetics, General Phase 4
40 Anesthetics, Intravenous Phase 4
41
Apatinib Phase 4 811803-05-1
42 Endostatins Phase 4 71581480
43 Natriuretic Peptide, Brain Phase 4
44 Ibandronic Acid Phase 4
45
L-Alanine Nutraceutical Phase 4 56-41-7 5950
46
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
47
Nadroparin Approved, Investigational Phase 3
48
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
49
Rocuronium Approved Phase 2, Phase 3 119302-91-9, 143558-00-3 441290
50
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757

Interventional clinical trials:

(show top 50) (show all 5095)
# Name Status NCT ID Phase Drugs
1 Efficacy of Nebulized Pulmicort Respules on Post Operation Pulmonary Complication During Pulmonary Single Lobectomy Surgery in Primary Lung Cancer Patients With COPD Unknown status NCT02504801 Phase 4 Budesonide
2 A Study of Endostar in Combination With Chemotherapy Followed by Endostar Maintenance Therapy in Patients With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) Unknown status NCT01028729 Phase 4 Endostar;Gemcitabine-Cisplatin chemotherapy
3 The Exploratory Clinical Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin (Endostar) for Local Advanced Non-small Cell Lung Cancer (NSCLC (Ⅲ A / Ⅲ B) ) Unknown status NCT01211002 Phase 4 radiotherapy / EP combined with recombinant human endostatin
4 A Randomized ,Opened, Prospective Controlled Trial of Clinical Effectiveness for Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With Epidermal Growth Factor Receptor Gene Mutation Unknown status NCT02283424 Phase 4 Icotinib;chemotherapy (Carboplatin and Docetaxel)
5 A Randomized,Double-blind,Placebo-Controlled,Multicenter Clinical Trail of Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT02195453 Phase 4 Yangzhengxiaoji Capsule;Placebo Capsule
6 Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Untreated Advanced Non-small-cell Lung Cancer: a Randomized, Open-label Study Unknown status NCT02194556 Phase 4 Sequential and maintenance icotinib;Maintenance icotinib
7 Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer: a Multi-center, Randomized, Open Label Study Unknown status NCT02348450 Phase 4 Irinotecan;Etoposide;Cisplatin
8 The Randomized Controlled Clinical Trial of Kushen Injection Reducing Radiotherapy Related Adverse Reactions in Lung Cancer Unknown status NCT02346318 Phase 4 Compound Kushen Injection
9 Maintenance Gemcitabine or Best Supportive Care for the Chinese Advanced NSCLC Patients Without Progression Disease After Given Four Cycles of the Induction Chemotherapy With Gemcitabine Plus Cisplatin Unknown status NCT01336192 Phase 4 Gemcitabine;Best supportive care
10 Safety Evaluation of Dexmedetomidine Monitored Anesthesia Care for Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Unknown status NCT01381627 Phase 4 Remifentanil;Dexmedetomidine
11 Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research Unknown status NCT02513355 Phase 4 Changchun marina;cisplatin;Taxol;parapl
12 Randomised, Controlled Study Comparing Chemotherapy Plus Intercalated EGFR-Tyrosine Kinase Inhibitors Combination Therapy With EGFR-Tyrosine Kinase Inhibitors Alone Therapy as First-line Treatment for Patients With Non-Small-Cell Lung Cancer Unknown status NCT02031601 Phase 4 Erlotinib;Gefitinib;Icotinib;Docetaxel;Pemetrexed;Platinum (cisplatin or carboplatin);Erlotinib;Gefitinib;Icotinib
13 PET/CT and Roentgen in Lung Cancer. Evaluation of Patients in General Practice Unknown status NCT00675168 Phase 4
14 A Double-blind, Randomized, Placebo-controlled Study to Compare the Effectiveness of IV Acetaminophen Administered Intra-operatively in Reducing the Use of Opiates to Treat Post-operative Pain Completed NCT01783236 Phase 4 IV Acetaminophen;Saline Placebo
15 A Single Arm, Open Label, Perspective Study to Determine the Efficacy and Safety of Icotinib Combine Cryotherapy for Advanced NSCLC Patients Completed NCT02744664 Phase 4 Icotinib
16 Safety Study of Nivolumab for Selected Advanced Malignancies in India Completed NCT03444766 Phase 4 Nivolumab
17 Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis Completed NCT00762346 Phase 4 zometa
18 A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Completed NCT01066884 Phase 4 erlotinib [Tarceva]
19 A Study of Erlotinib (Tarceva®) Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Completed NCT01287754 Phase 4 erlotinib [Tarceva]
20 A Pilot Study of the Effects of Neutropenia on Patient Reported Outcomes During Chemotherapy With or Without Neulasta® (Pegfilgrastim) in Subjects With Advanced NSCLC Completed NCT00115206 Phase 4 Neulasta® (pegfilgrastim)
21 An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Stage IIIB/IV Non-Small Cell Lung Cancer Completed NCT00949910 Phase 4 Erlotinib
22 Anesthesia in Flexible Bronchoscopy for Lung Cancer Diagnostic Completed NCT00440960 Phase 4 propofol;midazolam;alfentanil;lidocaine
23 A Multi-center Observational Clinical Study of Screening of Non-small-cell Lung Cancer With Bone Metastasis and Efficacy and Safety of Those Receiving Bisphosphonates Completed NCT00765687 Phase 4 bisphosphates
24 An International Expanded Access Clinical Programme With ZD1839 (IRESSATM) for Patients With Advanced Non-small Cell Lung Cancer (NSCLC) China Amendment 1: A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa Completed NCT01000740 Phase 4
25 Post-marketing Clinical Trial of Induction Chemotherapy of Pemetrexed Plus Carboplatin Followed by Pemetrexed Maintenance Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer Completed NCT01020786 Phase 4 Pemetrexed;Carboplatin
26 A Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemo-naive, Advanced, Non-Small-Cell Lung Cancer Patients Aged 70 Years or Older in Taiwan Completed NCT01196078 Phase 4 erlotinib [Tarceva];vinorelbine
27 A Multi-centre, Open-label, Phase IV, Interventional Study to Evaluate the Efficacy of Erlotinib (Tarceva®) Following 4 Cycles of Platinum-based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Experienced Disease Progression or Unacceptable Toxicity During Chemotherapy Completed NCT01230710 Phase 4 Erlotinib
28 Medical and Economic Evaluation of FORESEAL Versus the Current Therapeutic Approach (Stapling Alone or Associated With Tissue Sealant) in Terms of Air Leakage Duration After Lung Resection for Cancer. Completed NCT00925444 Phase 4
29 Effects of Different Doses of Methylprednisolone on Immunological Function and Postoperative Adverse Reaction of Patients After Radical Resection of Lung Cancer by Thoracoscope Completed NCT03393949 Phase 4 Methylprednisolone 1 mg•kg-1;Methylprednisolone 0.5mg•kg-1
30 Clinical Study of Recombinant Human Endostatin Combined With NP Chemotherapy in the Treatment of Stage ⅢA Non Small Cell Lung Cancer Completed NCT02497118 Phase 4 Endostatin;Vinorelbine;Cisplatin
31 A Placebo-Controlled, Multicentre, Randomised, Parallel Group, Trial to Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (StageIIIB/IV) Non Small Cell Lung Cancer (NSCLC) Chinese Patients Who HaveNot Experienced Disease Progression or Unacceptable Toxicity During Front Line Standard Platinum-Based Chemotherapy Completed NCT00770588 Phase 4 Gefitinib;Placebo
32 Open-Label Single-Arm Phase IV Study of Pemetrexed in Taiwanese Patients With Advanced Non-Small Cell Lung Cancer Who Have Had Prior Chemotherapy Completed NCT00380718 Phase 4 pemetrexed
33 "Red Morphine Drops" for Symptomatic Treatment of Dyspnoea in Terminal Patients With Primary Lung Cancer or Lung metastases-a Pilot Study Completed NCT00338481 Phase 4 Morphine p.o.;Morphine s.c.
34 Evaluation of the Usefulness of DurogesicD-TRANS for Pain Treatment in Lung Cancer Patients Completed NCT01060137 Phase 4 fentanyl matrix
35 A Multi-centric, Open-label, Phase II Study Investigating the Combination of Afinitor With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced (Stage IV) Large Cell Lung Cancer With Neuroendocrine Differentiation (LC-NEC) Completed NCT01317615 Phase 4 RAD001;Paclitaxel;Carboplatin
36 ONCOXIN® and Quality of Life in Cancer Patients in a Real World Setting Study Completed NCT03550482 Phase 4
37 A Dual-Cohort, Prospective, Observational Study of Unresectable Stage IIIB/IV Non-Small Cell Lung Cancer Patients With and Without Bone Metastasis Completed NCT00099541 Phase 4 zoledronic acid
38 Multicenter Exploratory Trial of the Safety and Efficacy of Adjuvant Docetaxel and Carboplatin in Patients With Resected Non-small Cell Lung Cancer Completed NCT00883675 Phase 4 Docetaxel-Carboplatin
39 A Study Of Cryospray Ablationtm Using Surgical Resection Specimens To Determine Safety And Histological Effect In The Lung Completed NCT00747773 Phase 4
40 Safety and Efficacy of Nab-paclitaxel (Abraxane) in Combination With Carboplatin as First Line Treatment in Elderly Subjects With Advance Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study (Abound.70+) Completed NCT02151149 Phase 4 nab-paclitaxel;Carboplatin
41 Open-label Study of Bevacizumab (AVASTIN®) in Combination With Platinum-containing Chemotherapy as First-line Treatment of Patients With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer Completed NCT00451906 Phase 4 Platinum-based chemotherapy;Bevacizumab [Avastin]
42 Coagulation Profile in Patients Undergoing Video Assisted Thorascopic Surgery (VATS) for Lung Cancer - A Randomized, Controlled Trial Completed NCT01741506 Phase 4 Dalteparin (Fragmin®)
43 Safety of Low Dose Intravenous Contrast 64 Multi-Detector Computed Tomography Scanning in Patients With Chronic Kidney Disease Completed NCT02476526 Phase 4 Low Volume iso-osmolar non-ionic radio contrast medium;Acetylcysteine Inhalation;Sodium Bicarbonate Solution
44 Conventional Versus Ultrasound-guided Transbronchial Needle Aspiration, Using Rapid On-site Cytological Evaluation, for the Diagnosis of Hilar/Mediastinal Enlarged Lymph Nodes: a Randomized Controlled Trial. Completed NCT01658280 Phase 4
45 Phase IV Randomized Trial of Pemetrexed Followed by Docetaxel or in Reverse Sequence in Non-small-cell Lung Cancer Patients Failed Previous Chemotherapy Completed NCT01442909 Phase 4 Docetaxel and pemetrexed
46 Phase IV/II Open-label Study to Evaluate Prompt Response to Treatment With Cisplatin, Gemcitabine and Bevacizumab in Patients With Non-small Lung Cancer. Completed NCT02316327 Phase 4 gemcitabine, cisplatin and bevacizumab
47 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
48 Phase IV Study of Concurrent Chemoradiotherapy With Paclitaxel and Cisplatin in Previously Untreated, Inoperable (Stage IIIa or IIIb) Non-small-cell Lung Cancer Completed NCT00686322 Phase 4 Concurrent chemoradiotherapy (paclitaxel plus cisplatin plus radiotherapy)
49 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
50 Effect Of Ketamine Infusion On Oxygenation And Ventilation Mechanics In Patients With Chronic Obstructive Pulmonary Disease Applied One Lung Ventilation Completed NCT02962999 Phase 4 Ketamine;Saline

Search NIH Clinical Center for Lung Benign Neoplasm

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Carboplatin
Carmustine
Cholecalciferol
Cisplatin
CISPLATIN PWDR
Cyclophosphamide
Etoposide
etoposide phosphate
Ifosfamide
Lomustine
Methotrexate
Methotrexate Sodium
Paclitaxel
Procarbazine
Procarbazine Hydrochloride
Teniposide
Vinblastine
Vinblastine Sulfate

Cochrane evidence based reviews: lung neoplasms

Genetic Tests for Lung Benign Neoplasm

Anatomical Context for Lung Benign Neoplasm

MalaCards organs/tissues related to Lung Benign Neoplasm:

40
Lung, Brain, Testes, Breast, T Cells, Lymph Node, Bone

Publications for Lung Benign Neoplasm

Articles related to Lung Benign Neoplasm:

(show top 50) (show all 1168)
# Title Authors PMID Year
1
GCDFP-15 positive and TTF-1 negative primary lung neoplasms: a tissue microarray study of 381 primary lung tumors. 61 54
19620839 2009
2
Genetic alterations in K-ras and p53 cancer genes in lung neoplasms from Swiss (CD-1) male mice exposed transplacentally to AZT. 54 61
16395694 2007
3
Expression of matrix metalloproteinases 3, 10 and 11 (stromelysins 1, 2 and 3) and matrix metalloproteinase 7 (matrilysin) by cancer cells in non-small cell lung neoplasms. Clinicopathologic studies. 54 61
16506596 2006
4
Expression of Pirh2, a newly identified ubiquitin protein ligase, in lung cancer. 61 54
15547185 2004
5
The utility and limitation of thyroid transcription factor-1 protein in primary and metastatic pulmonary neoplasms. 54 61
15084379 2004
6
Dysregulated secretoglobin expression in human lung cancers. 54 61
12826312 2003
7
[Molecular targetting therapy for non-small-cell lung neoplasms with EGF-R inhibitors]. 54 61
12652739 2003
8
Immunoreactivity for epithelial and neuroendocrine antibodies are useful in the differential diagnosis of lung carcinomas. 61 54
10987260 2000
9
Mechanism of retinoblastoma gene inactivation in the spectrum of neuroendocrine lung tumors. 54 61
9476905 1998
10
Membrane-bound (MUC1) and secretory (MUC2, MUC3, and MUC4) mucin gene expression in human lung cancer. 61 54
8638091 1996
11
Analysis of K-ras, p53 and c-raf-1 mutations in beryllium-induced rat lung tumors. 61 54
7545909 1994
12
Expression of epidermal growth factor receptor in plutonium-239-induced lung neoplasms in dogs. 61 54
1313613 1992
13
[Usefulness of simultaneous antigenic determination of carcinoembryonic antigen (CEA), ferritin and orosomucoid levels in diagnosis of lung neoplasms]. 61 54
1843646 1991
14
PD-1/PD-L1 negative schwannoma mimicking obstructive bronchial malignancy: A case report. 61
32510862 2020
15
Diagnostic yield of rapid on-site evaluation transbronchial needle aspiration versus conventional transbronchial needle aspiration: a single center experience. 61
32293166 2020
16
[The development and validation of risk prediction model for lung cancer: a systematic review]. 61
32268653 2020
17
CT Halo sign: A systematic review. 61
32007819 2020
18
SAEROF: an ensemble approach for large-scale drug-disease association prediction by incorporating rotation forest and sparse autoencoder deep neural network. 61
32188871 2020
19
Diffusion-Weighted MR Imaging of Primary and Secondary Lung Cancer: Predictive Value for Response to Transpulmonary Chemoembolization and Transarterial Chemoperfusion. 61
31899107 2020
20
Psychosocial interventions for informal caregivers of lung cancer patients: A systematic review. 61
31701588 2020
21
A Rare Cause of Cough: Tracheobronchial Myxoid Spindle Cell Lipoma. 61
32551146 2020
22
mTOR in Lung Neoplasms. 61
32016810 2020
23
CT-based radiomics for prediction of histologic subtype and metastatic disease in primary malignant lung neoplasms. 61
31722085 2020
24
Classification and Imaging Findings of Lung Neoplasms. 61
31964479 2020
25
A Computational Study of Potential miRNA-Disease Association Inference Based on Ensemble Learning and Kernel Ridge Regression. 61
32117922 2020
26
Chance to rein in a cancer--Spontaneous regression of lung carcinoma (1988-2018): a 30-year perspective. 61
32509094 2020
27
Bronchial Carcinoid Tumors with Massive Osseous Metaplasia: A Case Report and Review of the Literature. 61
30977863 2020
28
MSFSP: A Novel miRNA-Disease Association Prediction Model by Federating Multiple-Similarities Fusion and Space Projection. 61
32425980 2020
29
Lung cancer metastasis to the breast mimicking inflammatory breast carcinoma on imaging. 61
31660096 2019
30
Review: Alternative and New Radiopharmaceutical Agents for Lung Cancer. 61
31868150 2019
31
Bibliometrics of Tunisian publications on respiratory tract diseases from 2010 to 2014. 61
32173818 2019
32
Pulmonary carcinoid presenting with persistent pneumothorax. 61
31712234 2019
33
Risk of Cancer for Workers Exposed to Antimony Compounds: A Systematic Review. 61
31739404 2019
34
Predicting miRNA-Disease Associations by Incorporating Projections in Low-Dimensional Space and Local Topological Information. 61
31500152 2019
35
Incidental endobronchial hamartoma in a patient with enchondroma. 61
31527201 2019
36
Percutaneous radiofrequency ablation using internally cooled wet electrodes for the treatment of patients with lung tumors. 61
31378896 2019
37
Left Lung Neoplasms and Bilateral Pleural Effusion Combined Elevated Carcinoembryonic Antigen in Pleural Effusion with Negative Result of Thoracoscopy Pleural Biopsy Misdiagnosed as Lung Carcinoma Ultimately Confirmed Pulmonary Sarcomatoid Carcinoma by CT-guided Percutaneous Lung Biopsy: a Case Report and Literature Review. 61
31414757 2019
38
Embolization of Chest Neoplasms: The Next Frontier in Interventional Oncology? 61
31435125 2019
39
[Fluorescence Guided Sublobar Lung Resection by Using Three-dimensional Image Analysis and Transbronchial Instillation of Indocyanine Green]. 61
31296801 2019
40
MAMDA: Inferring microRNA-Disease associations with manifold alignment. 61
31154259 2019
41
Primary Pulmonary Involvement in Mucosa-associated Lymphoid Tissue Lymphoma. 61
31523541 2019
42
Prediction of Potential Disease-Associated MicroRNAs by Using Neural Networks. 61
31077936 2019
43
Spontaneous Partial Regression of a Carcinoid Tumor: Radiology May Not Capture the Real Picture. 61
30958990 2019
44
Surgical Treatment of Bilateral Lung Cancers: Long-Term Outcomes and Prognostic Factors. 61
30991418 2019
45
An integrated framework for the identification of potential miRNA-disease association based on novel negative samples extraction strategy. 61
30646823 2019
46
Inferring microRNA-disease association by hybrid recommendation algorithm and unbalanced bi-random walk on heterogeneous network. 61
30792474 2019
47
Approaches to Tumor Classification in Pulmonary Sarcomatoid Carcinoma. 61
31824199 2019
48
Insulinoma-associated protein 1 (INSM1) is a sensitive and highly specific marker of neuroendocrine differentiation in primary lung neoplasms: an immunohistochemical study of 345 cases, including 292 whole-tissue sections. 61
30154579 2019
49
A Rare Case of Primary Pulmonary Anaplastic Large Cell Lymphoma. 61
31583219 2019
50
Metachronous Pulmonary Neoplasms in Lung Transplantation-When They Arise in the Donor Lung: A Case Report. 61
30577319 2018

Variations for Lung Benign Neoplasm

Expression for Lung Benign Neoplasm

Search GEO for disease gene expression data for Lung Benign Neoplasm.

Pathways for Lung Benign Neoplasm

Pathways related to Lung Benign Neoplasm according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.55 TP53 RARB KRAS HRAS EGFR CDKN2A
2 12.53 TP53 RASSF1 RARB KRAS HRAS EGFR
3
Show member pathways
12.38 TP53 STK11 KRAS HRAS EGFR
4
Show member pathways
12.36 TP53 RASSF1 RARB KRAS HRAS FHIT
5 12.29 TP53 RASSF1 KRAS HRAS EGFR CDKN2A
6 12.27 TP53 KRAS HRAS CDKN2A
7 12.23 TP53 KRAS HRAS EGFR
8 12.22 TP53 KRAS HRAS CDKN2A
9
Show member pathways
12.22 TP53 KRAS HRAS EGFR
10 12.07 TP53 KRAS HRAS CDKN2A
11 12.05 TP53 STK11 KRAS EGFR
12
Show member pathways
12.02 TP53 STK11 KRAS HRAS
13
Show member pathways
11.98 TP53 KRAS HRAS EGFR
14
Show member pathways
11.96 STK11 KRAS HRAS EGFR
15 11.86 TP53 KRAS HRAS CDKN2A
16 11.63 TP53 KRAS HRAS
17 11.54 KRAS HRAS EGFR
18 11.51 TP53 KRAS HRAS EGFR
19 11.48 TP53 EGFR CDKN2A
20 11.48 TP53 MGMT KRAS HRAS EGFR CDKN2A
21 11.44 KRAS HRAS EGFR
22 11.36 KRAS HRAS EGFR
23 11.13 KRAS HRAS EGFR
24 11.06 RASSF1 KRAS EGFR
25
Show member pathways
11.02 KRAS HRAS EGFR
26 10.96 TP53 RASSF1 KRAS HRAS EGFR CDKN2A

GO Terms for Lung Benign Neoplasm

Biological processes related to Lung Benign Neoplasm according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.89 TP53 NKX2-1 KRAS HRAS CDKN2A
2 negative regulation of cell proliferation GO:0008285 9.88 TP53 STK11 RARB HRAS CDKN2A
3 apoptotic process GO:0006915 9.88 TP53 STK11 KRT20 HRAS FHIT CDKN2A
4 positive regulation of MAP kinase activity GO:0043406 9.63 KRAS HRAS EGFR
5 liver development GO:0001889 9.56 RARB KRAS HRAS EGFR
6 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.52 TP53 EGFR
7 cerebral cortex cell migration GO:0021795 9.51 NKX2-1 EGFR
8 intrinsic apoptotic signaling pathway by p53 class mediator GO:0072332 9.5 TP53 STK11 FHIT
9 response to isolation stress GO:0035900 9.43 KRAS HRAS
10 positive regulation of phospholipase C-activating G protein-coupled receptor signaling pathway GO:1900738 9.37 GRP CHGA
11 cell cycle arrest GO:0007050 9.35 TP53 STK11 RASSF1 HRAS CDKN2A
12 regulation of long-term neuronal synaptic plasticity GO:0048169 9.33 SYP KRAS HRAS
13 Ras protein signal transduction GO:0007265 9.02 TP53 RASSF1 KRAS HRAS CDKN2A

Molecular functions related to Lung Benign Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 LRR domain binding GO:0030275 8.62 STK11 KRAS

Sources for Lung Benign Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....